



NAC Statement on Fibrinogen Concentrate



NAC STATEMENT ON FIBRINOGEN CONCENTRATE WORKING GROUP

NAC Chair:	Oksana Prokopchuk Gauk, MD
Endorsement Working Group Members:	Katerina Pavenski, MD, Chair Taher Rad, MD Susan Nahirniak, MD
Provincial Ministry Representative:	Corinne Rowswell (PE)
NAC Coordinator:	Rony Skaff
Date of Original Release:	December 15, 2014
Date of Last Revision:	February 14, 2020
Publication Date:	April 9, 2020



TABLE OF CONTENTS

LIST OF ABBREVIATIONS	4
SUMMARY OF REVISIONS	5
SECTION 1.0: FIBRINOGEN CONCENTRATE DOSING	6
SECTION 2.0: FC PRODUCTS IN CANADA	7
REFERENCES	8



LIST OF ABBREVIATIONS

NAC	National Advisory Committee for Blood and Blood Products
FC	Fibrinogen concentrate



SUMMARY OF REVISIONS

Revision Date	Detail
February 2020	Added discussion on RiaSTAP and FIBRYGA as two brands of fibrinogen concentrate now available from CBS
	Added reference for the FIBRES study
	Added statement on fibrinogen concentrate having a favorable safety profile over cryoprecipitate or frozen plasma for fibrinogen replacement
July 2018	Addition of dosing recommendations for pediatric patients
	Clarified suggested fibrinogen replacement threshold for obstetrical patients



SECTION 1.0: FIBRINOGEN CONCENTRATE DOSING

Fibrinogen replacement plays an important role in management of massive bleeding post cardiac surgery, trauma and obstetrical hemorrhage among others. However, there continues to be a lack of evidence firmly guiding fibrinogen replacement product choice as well as ongoing uncertainties as to the optimal target and dose. Fibrinogen concentrate (FC), frozen plasma (FP), and cryoprecipitate are currently used to treat acquired hypofibrinogenemia, while fibrinogen concentrate is licensed for treatment of congenital hypofibrinogenemia.

Fibrinogen content of the above mentioned products is as follows (1-4):

- 1 vial FC = 0.9 – 1.3 g fibrinogen
- 1000 mL FP = 2.94 +/- 0.63 g fibrinogen (1 SD)
- 1 unit cryoprecipitate = 0.285 +/- 0.088 g fibrinogen (1 SD) or no more than 5g of fibrinogen per pool of 10 units (D. Devine (dana.devine@blood.ca), email communication December 14 2019).

Optimal dosing of the above mentioned products is affected by:

- The inter-donor variability of fibrinogen content in blood components
- Each unique patient clinical situation, including size, amount and rate of bleeding, baseline fibrinogen level, liver synthetic function and underlying diagnosis.

In a bleeding obstetrical patient with acquired hypofibrinogenemia, fibrinogen replacement is indicated when fibrinogen level is less than 2.0g/L (5). In a massively bleeding or preoperative patient with acquired hypofibrinogenemia, fibrinogen should be replaced when the level is less than 1.5g/L (6-8).

The following fibrinogen replacement options with suggested doses may be used in hypofibrinogenemic adult patients:

- FC: 2-4g
- FP: 3-4 units (10-15 mL/kg)
- Cryoprecipitate: 10 units (1 unit/10 kg)

In neonates and pediatric patients, it is recommended to consult with the product monograph and a specialist with expertise in managing pediatric/neonatal coagulopathy prior to administration of fibrinogen concentrates. In published studies (9-11) of acquired hypofibrinogenemia in neonatal or pediatric populations, fibrinogen concentrate dosing has ranged between 30-60 mg/kg.



SECTION 2.0: FC PRODUCTS IN CANADA

There are two FC products currently available in Canada: RiaSTAP (CSL Behring) and FIBRYGA (Octapharma) (3,4). Both are licensed for congenital hypofibrinogenemia. The use of fibrinogen concentrate in acquired hypofibrinogenemia is currently off-label, but is supported in bleeding cardiovascular patients by a recent high-quality randomized trial (12).

According to data provided by the manufacturers, in addition to fibrinogen, fibrinogen concentrates contain trace amounts of the other substances, such as FXIII and fibronectin. These substances are not listed as active ingredients in the product monograph and the concentrations in the final product may vary. As such, their clinical relevance, if any, is unknown. Furthermore, both fibrinogen concentrates appear to have similar efficacy in improving clot firmness in a dilutional hypofibrinogenemia model *in vitro* (13).

The major difference between these products is related to the product storage: FIBRYGA is stored at room temperature for up to 36 months whereas RiaSTAP is stored in a refrigerator for up to 60 months (3,4).

At this time, there is no evidence of superiority of one fibrinogen replacement over the others in terms of clinical efficacy. However, fibrinogen concentrate is pathogen inactivated and has a preferred safety profile in terms of transmissible disease risk as compared to frozen plasma and cryoprecipitate. Furthermore, fibrinogen concentrate offers many logistical advantages, including a more precise fibrinogen dose, simpler preparation (without need for thawing and with capability for bedside reconstitution), and efficiency of administration.



REFERENCES

1. Circular of Information for the Use of Human Blood Components: Plasma Components. https://blood.ca/sites/default/files/COI_CPDPlasmaFFPA.pdf. Accessed May 29, 2018.
2. Sheffield WP et al. Quality of frozen transfusable plasma prepared from whole blood donations in Canada: An update. *Transfusion and Apheresis Science*. 2013;Vol 49(3): 440-446.
3. CSL Behring. RiaSTAP® Fibrinogen Concentrate (Human) product monograph, approved May 22 2019, control number 226989. <http://labeling.cslbehring.ca/PM/CA/RiaSTAP/EN/RiaSTAP-Product-Monograph.pdf>. Accessed February 6 2020.
4. Octapharma. fibryga Fibrinogen Concentrate (Human) Product Monograph. Approved August 10 2018, control number 215808. https://www.octapharma.ca/fileadmin/user_upload/octapharma.ca/Product_Monographs/FIBRYGA-PM-EN.pdf. Accessed February 6 2020.
5. Collins RE, Collins PW. Haemostatic management of obstetric haemorrhage. *Anaesthesia*. 2015; 70(Suppl. 1):78-86.
6. Wada H, Thachil J, Di Nisio M, et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. *J Thromb Haemost*. 2013;11:761-7.
7. Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. *Transfusion*. 2014; 54:1389-405.
8. Levy JH, Goodnough LT. How I use fibrinogen replacement therapy in acquired bleeding. *Blood*. 2015 Feb 26;125(9):1387-93.
9. Haas T, Fries D, Velik-Salchner C, Oswald E, Innerhofer P. Fibrinogen in craniostomy surgery. *Anesthesia & Analgesia*. 2008;106(3):725-731.
10. Galas FRBG, de Almeida JP, Fukushima JT, et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. *Journal of Thoracic and Cardiovascular Surgery*. 2014;148:1647-55.
11. Lier H, von Heymann C, Korte W, et al. Peripartum Haemorrhage: Haemostatic Aspects of the New German PPH Guideline. *Transfus Med Hemother*. 2018 Apr;45(2):127-135.



12. Callum J, Farkouh ME, Scales DC, et al. Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical Trial. *JAMA*. Published online October 21, 2019. doi:<https://doi.org/10.1001/jama.2019.17312>.

13. Haas T, Cushing MM, Asmis LM. Comparison of the efficacy of two human fibrinogen concentrates to treat dilutional coagulopathy in vitro. *Scand J Clin Lab Invest*. 2018 May;78(3):230-235.